$Myovant Sciences Ltd.(MYOV)$reasons to buy…1) great fundamentals a) 2 approved life saving/changing blockbusters and more pending b) strong financials - huge cash runwayc) Experienced Pfizer commercialising the above drugs.. acknowledging the value with 4.2b tiered payment 2) Buyout Target for Sumi who is facing a patent cliff and can fully own last of the “vant” company or secondary contender PFizer who is flooded with cash and looking to buy. Lots of M&A happening in this space3)Fantastic Value and looking at a reversal trend. Cyclical move into biomed.. great oppty and timing for the buyout before price become higher…
$Calliditas Therapeutics AB(CALT)$$Myovant Sciences Ltd.(MYOV)$$MYOV reasons to buy…1) great fundamentals a) 2 approved life saving/changing blockbusters and more pending b) strong financials - huge cash runwayc) Experienced Pfizer commercialising the above drugs.. acknowledging the value with 4.2b tiered payment 2) Buyout Target for Sumi who is facing a patent cliff and can fully own last of the “vant” company or secondary contender PFizer who is flooded with cash and looking to buy. Lots of M&A happening in this space3)Fantastic Value and looking at a reversal trend. Cyclical move into biomed.. great oppty and timing for the buyout before price become higher…
$Kweichow Moutai Co.,Ltd.(600519)$$Myovant Sciences Ltd.(MYOV)$MYOV now Trading below its IPO price when there was nothing… 2 blockbuster drugs approved and commercialization by Pfizer at tiered payment of 4.2billion for half the sales. Sales has started and growing steadily with good reviews from practicitors… One more drug pending approval and Sumi looking at acquiring the last “vant” company to make upfor the patent cliff made MYOV an irresitiable target to buy.. another contender will be Pfizer who is flooded with cash and out on a buying spree.. either one move and we will have a winner here… trading well below valuation at this price…Greatvalue at 3 times better price to sales ratio versus last quarter
$Beigene, Ltd.(688235)$$Myovant Sciences Ltd.(MYOV)$MYOV now Trading below its IPO price when there was nothing… 2 blockbuster drugs approved and commercialization by Pfizer at tiered payment of 4.2billion for half the sales. Sales has started and growing steadily with good reviews from practicitors… One more drug pending approval and Sumi looking at acquiring the last “vant” company to make upfor the patent cliff made MYOV an irresitiable target to buy.. another contender will be Pfizer who is flooded with cash and out on a buying spree.. either one move and we will have a winner here… trading well below valuation at this price…Greatvalue at 3 times better price to sales ratio versus last quarter a